10-May-2024
Veracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy Rating
TipRanks (Fri, 10-May 4:35 AM ET)
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
TipRanks (Fri, 10-May 4:30 AM ET)
Veracyte’s Robust Performance and Growth Potential Reinforce Buy Rating
TipRanks (Fri, 10-May 1:18 AM ET)
TipRanks (Wed, 8-May 7:20 AM ET)
Maintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward Profitability
TipRanks (Wed, 8-May 7:15 AM ET)
CRUS, ZI and VCYT are among after hour movers
Seeking Alpha News (Tue, 7-May 5:54 PM ET)
Veracyte GAAP EPS of -$0.02 beats by $0.13, revenue of $96.84M beats by $3.48M
Seeking Alpha News (Tue, 7-May 4:17 PM ET)
Veracyte Announces First Quarter 2024 Financial Results
Business Wire (Tue, 7-May 4:05 PM ET)
Business Wire (Mon, 6-May 4:05 PM ET)
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
Business Wire (Mon, 22-Apr 5:00 PM ET)
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Veracyte trades on the NASDAQ stock market under the symbol VCYT.
As of May 10, 2024, VCYT stock price climbed to $21.37 with 1,020,542 million shares trading.
VCYT has a beta of 2.44, meaning it tends to be more sensitive to market movements. VCYT has a correlation of 0.39 to the broad based SPY ETF.
VCYT has a market cap of $1.63 billion. This is considered a Small Cap stock.
Last quarter Veracyte reported $97 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.15.
In the last 3 years, VCYT stock traded as high as $54.13 and as low as $14.85.
The top ETF exchange traded funds that VCYT belongs to (by Net Assets): ARKK, VTI, XBI, VB, ARKG.
VCYT has underperformed the market in the last year with a return of -9.6%, while the SPY ETF gained +27.8%. In the last 3 month period, VCYT fell short of the market, returning -16.4%, while SPY returned +4.2%. However, in the most recent 2 weeks VCYT has outperformed the stock market by returning +10.7%, while SPY returned +2.5%.
VCYT support price is $19.96 and resistance is $21.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCYT stock will trade within this expected range on the day.